Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v3.8.0.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Consolidated Statements Of Operations    
Revenues, net $ 657,271 $ 701,772
Operating expenses:    
Cost of implants and other costs 323,608 175,430
Research and development 450,722
Selling, general and administrative 2,739,967 2,545,311
Termination of licensing agreement 132,804
Depreciation and amortization 33,888 30,248
Total operating expenses 3,548,185 2,883,793
Loss from operations (2,890,914) (2,182,021)
Other income (expenses):    
Gain on settlement of debt 296,592
Interest expense, net (11,148,525) (1,048,013)
Loss on change in fair value of derivative liability (15,962,822) (2,673,948)
Total other income (expenses) (26,814,755) (3,721,961)
Loss before income taxes (29,705,669) (5,903,982)
Income taxes
Net Loss $ (29,705,669) $ (5,903,982)
Net loss per common share, basic and diluted $ (0.13) $ (0.03)
Weighted average number of common shares outstanding, basic and diluted 232,678,553 170,245,976